Literature DB >> 28651474

Epidemiology and Changes in Mortality of Sepsis After the Implementation of Surviving Sepsis Campaign Guidelines.

Rubén Herrán-Monge1, Arturo Muriel-Bombín1, Marta M García-García1, Pedro A Merino-García1, Miguel Martínez-Barrios2, David Andaluz3, Juan Carlos Ballesteros4, Ana María Domínguez-Berrot5, Susana Moradillo-Gonzalez6, Santiago Macías7, Braulio Álvarez-Martínez8, M José Fernández-Calavia9, Concepción Tarancón10, Jesús Villar11,12, Jesús Blanco1,11.   

Abstract

PURPOSE: To determine the epidemiology and outcome of severe sepsis and septic shock after 9 years of the implementation of the Surviving Sepsis Campaign (SSC) and to build a mortality prediction model.
METHODS: This is a prospective, multicenter, observational study performed during a 5-month period in 2011 in a network of 11 intensive care units (ICUs). We compared our findings with those obtained in the same ICUs in a study conducted in 2002.
RESULTS: The current cohort included 262 episodes of severe sepsis and/or septic shock, and the 2002 cohort included 324. The prevalence was 14% (95% confidence interval: 12.5-15.7) with no differences to 2002. The population-based incidence was 31 cases/100 000 inhabitants/year. Patients in 2011 had a significantly lower Acute Physiology and Chronic Health Evaluation II (APACHE II; 21.9 ± 6.6 vs 25.5 ± 7.07), Logistic Organ Dysfunction Score (5.6 ± 3.2 vs 6.3 ± 3.6), and Sequential Organ Failure Assessment (SOFA) scores on day 1 (8 ± 3.5 vs 9.6 ± 3.7; P < .01). The main source of infection was intraabdominal (32.5%) although microbiologic isolation was possible in 56.7% of cases. The 2011 cohort had a marked reduction in 48-hour (7% vs 14.8%), ICU (27.2% vs 48.2%), and in-hospital (36.7% vs 54.3%) mortalities. Most relevant factors associated with death were APACHE II score, age, previous immunosuppression and liver insufficiency, alcoholism, nosocomial infection, and Delta SOFA score.
CONCLUSION: Although the incidence of sepsis/septic shock remained unchanged during a 10-year period, the implementation of the SSC guidelines resulted in a marked decrease in the overall mortality. The lower severity of patients on ICU admission and the reduced early mortality suggest an improvement in early diagnosis, better initial management, and earlier antibiotic treatment.

Entities:  

Keywords:  Surviving Sepsis Campaign; epidemiology; mortality; organ failure; septic shock; severe sepsis

Mesh:

Year:  2017        PMID: 28651474     DOI: 10.1177/0885066617711882

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  19 in total

1.  Follicular dendritic cell dysfunction contributes to impaired antigen-specific humoral responses in sepsis-surviving mice.

Authors:  Minakshi Rana; Andrea La Bella; Rivka Lederman; Bruce T Volpe; Barbara Sherry; Betty Diamond
Journal:  J Clin Invest       Date:  2021-06-15       Impact factor: 14.808

Review 2.  Data Science Methods for Nursing-Relevant Patient Outcomes and Clinical Processes: The 2019 Literature Year in Review.

Authors:  Mary Anne Schultz; Rachel Lane Walden; Kenrick Cato; Cynthia Peltier Coviak; Christopher Cruz; Fabio D'Agostino; Brian J Douthit; Thompson Forbes; Grace Gao; Mikyoung Angela Lee; Deborah Lekan; Ann Wieben; Alvin D Jeffery
Journal:  Comput Inform Nurs       Date:  2021-05-06       Impact factor: 1.985

3.  Effectiveness of automated alerting system compared to usual care for the management of sepsis.

Authors:  Zhongheng Zhang; Lin Chen; Ping Xu; Qing Wang; Jianjun Zhang; Kun Chen; Casey M Clements; Leo Anthony Celi; Vitaly Herasevich; Yucai Hong
Journal:  NPJ Digit Med       Date:  2022-07-19

4.  Risk Factors for Maternal Readmission with Sepsis.

Authors:  Megan E Foeller; Lillian Sie; Timothy M Foeller; Anna I Girsen; Suzan L Carmichael; Deirdre J Lyell; Henry C Lee; Ronald S Gibbs
Journal:  Am J Perinatol       Date:  2019-09-17       Impact factor: 1.862

Review 5.  Recent Advances in the Molecular Mechanisms Underlying Pyroptosis in Sepsis.

Authors:  Yu-Lei Gao; Jian-Hua Zhai; Yan-Fen Chai
Journal:  Mediators Inflamm       Date:  2018-03-07       Impact factor: 4.711

Review 6.  Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis.

Authors:  C Fleischmann-Struzek; L Mellhammar; N Rose; A Cassini; K E Rudd; P Schlattmann; B Allegranzi; K Reinhart
Journal:  Intensive Care Med       Date:  2020-06-22       Impact factor: 17.440

7.  P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis.

Authors:  Juan José Martínez-García; Helios Martínez-Banaclocha; Diego Angosto-Bazarra; Carlos de Torre-Minguela; Alberto Baroja-Mazo; Cristina Alarcón-Vila; Laura Martínez-Alarcón; Joaquín Amores-Iniesta; Fátima Martín-Sánchez; Giovanni A Ercole; Carlos M Martínez; Ada González-Lisorge; José Fernández-Pacheco; Piedad Martínez-Gil; Sahil Adriouch; Friedrich Koch-Nolte; Juan Luján; Francisco Acosta-Villegas; Pascual Parrilla; Carlos García-Palenciano; Pablo Pelegrin
Journal:  Nat Commun       Date:  2019-06-20       Impact factor: 14.919

8.  Sepsis information-seeking behaviors via Wikipedia between 2015 and 2018: A mixed methods retrospective observational study.

Authors:  Craig S Jabaley; Robert F Groff; Theresa J Barnes; Mark E Caridi-Scheible; James M Blum; Vikas N O'Reilly-Shah
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

9.  Sequential Organ Failure Assessment Component Score Prediction of In-hospital Mortality From Sepsis.

Authors:  Tushar Gupta; Michael A Puskarich; Elizabeth DeVos; Adnan Javed; Carmen Smotherman; Sarah A Sterling; Henry E Wang; Frederick A Moore; Alan E Jones; Faheem W Guirgis
Journal:  J Intensive Care Med       Date:  2018-08-30       Impact factor: 3.510

10.  PCR-based Sepsis@Quick test is superior in comparison with blood culture for identification of sepsis-causative pathogens.

Authors:  Ngo Tat Trung; Nguyen Sy Thau; Mai Hong Bang; Le Huu Song
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.